Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BATMAN: Bevacizumab + Taxane in TNBC
NCT01094184Phase 4Completed
- Sponsor
- Roche
- Start
- Mar 2010
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Roche. Primary endpoints: Functional Assessment of Cancer Therapy-Breast Cancer, Euro Quality of Life - Health State Questionnaire and 1 more. Started Mar 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01094184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094184.